2-Year Outcomes of an Atrial Shunt Device in HFpEF/HFmrEF: Results From REDUCE LAP-HF II.

The REDUCE LAP-HF II (Reduce Elevated Left Atrial Pressure in Patients With Heart Failure II) trial found that, compared with a sham procedure, the Corvia Atrial Shunt did not improve outcomes in heart failure with preserved or mildly reduced ejection fraction. However, after 12-month follow-up, "responders" (peak-exercise pulmonary vascular resistance <1.74 WU and absence of a cardiac rhythm management device) were identified. This study sought to determine: 1) the overall efficacy and safety of the atrial shunt vs sham control after 2 years of follow-up; and 2) whether the benefits of atrial shunting are sustained in responders during longer-term follow-up or are offset by adverse effects of the shunt. The study analyzed 2-year outcomes in the overall REDUCE LAP-HF II trial, as well as in responder and nonresponder subgroups. The primary endpoint was a hierarchical composite of cardiovascular death or nonfatal ischemic/embolic stroke, total heart failure events, and change in health status. In 621 randomized patients, there was no difference between the shunt (n = 309) and sham (n = 312) groups in the primary endpoint (win ratio: 1.01 [95% CI: 0.82-1.24]) or its individual components at 2 years. Shunt patency at 24 months was 98% in shunt-treated patients. Cardiovascular mortality and nonfatal ischemic stroke were not different between the groups; however, major adverse cardiac events were more common in those patients assigned to the shunt compared with sham (6.9% vs 2.7%; P = 0.018). More patients randomized to the shunt had an increase in right ventricular volume of ≥30% compared with the sham control (39% vs 28%, respectively; P < 0.001), but right ventricular dysfunction was uncommon and not different between the treatment groups. In responders (n = 313), the shunt was superior to sham (win ratio: 1.36 [95% CI: 1.02-1.83]; P = 0.037, with 51% fewer HF events [incidence rate ratio: 0.49 [95% CI: 0.25-0.95]; P = 0.034]). In nonresponders (n = 265), atrial shunting was inferior to sham (win ratio: 0.73 [95% CI: 0.54-0.98]). At 2 years of follow-up in REDUCE LAP-HF II, there was no difference in efficacy between the atrial shunt and sham groups in the overall trial group. The potential clinical benefit identified in the responder group after 1 and 2 years of follow-up is currently being evaluated in the RESPONDER-HF (Re-Evaluation of the Corvia Atrial Shunt Device in a Precision Medicine Trial to Determine Efficacy in Mildly Reduced or Preserved Ejection Fraction Heart Failure) trial. (Reduce Elevated Left Atrial Pressure in Patients With Heart Failure II [REDUCE LAP-HF II]; NCT03088033).

Gustafsson F ，Petrie MC ，Komtebedde J ，Swarup V ，Winkler S ，Hasenfuß G ，Borlaug BA ，Mohan RC ，Flaherty JD ，Sverdlov AL ，Fail PS ，Chung ES ，Lurz P ，Lilly S ，Kaye DM ，Cleland JGF ，Cikes M ，Leon MB ，Cutlip DE ，van Veldhuisen DJ ，Solomon SD ，Shah SJ ... -  《-》

Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: The REDUCE LAP-HF II Randomized Clinical Trial.

Patel RB ，Silvestry FE ，Komtebedde J ，Solomon SD ，Hasenfuß G ，Litwin SE ，Borlaug BA ，Price MJ ，Kawash R ，Hummel SL ，Cutlip DE ，Leon MB ，van Veldhuisen DJ ，Rieth AJ ，McKenzie S ，Bugger H ，Mazurek JA ，Kapadia SR ，Vanderheyden M ，Ky B ，Shah SJ ... -  《-》

Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial.

Placement of an interatrial shunt device reduces pulmonary capillary wedge pressure during exercise in patients with heart failure and preserved or mildly reduced ejection fraction. We aimed to investigate whether an interatrial shunt can reduce heart failure events or improve health status in these patients. In this randomised, international, blinded, sham-controlled trial performed at 89 health-care centres, we included patients (aged ≥40 years) with symptomatic heart failure, an ejection fraction of at least 40%, and pulmonary capillary wedge pressure during exercise of at least 25 mm Hg while exceeding right atrial pressure by at least 5 mm Hg. Patients were randomly assigned (1:1) to receive either a shunt device or sham procedure. Patients and outcome assessors were masked to randomisation. The primary endpoint was a hierarchical composite of cardiovascular death or non-fatal ischemic stroke at 12 months, rate of total heart failure events up to 24 months, and change in Kansas City Cardiomyopathy Questionnaire overall summary score at 12 months. Pre-specified subgroup analyses were conducted for the heart failure event endpoint. Analysis of the primary endpoint, all other efficacy endpoints, and safety endpoints was conducted in the modified intention-to-treat population, defined as all patients randomly allocated to receive treatment, excluding those found to be ineligible after randomisation and therefore not treated. This study is registered with ClinicalTrials.gov, NCT03088033. Between May 25, 2017, and July 24, 2020, 1072 participants were enrolled, of whom 626 were randomly assigned to either the atrial shunt device (n=314) or sham procedure (n=312). There were no differences between groups in the primary composite endpoint (win ratio 1·0 [95% CI 0·8-1·2]; p=0·85) or in the individual components of the primary endpoint. The prespecified subgroups demonstrating a differential effect of atrial shunt device treatment on heart failure events were pulmonary artery systolic pressure at 20W of exercise (pinteraction=0·002 [>70 mm Hg associated with worse outcomes]), right atrial volume index (pinteraction=0·012 [≥29·7 mL/m2, worse outcomes]), and sex (pinteraction=0·02 [men, worse outcomes]). There were no differences in the composite safety endpoint between the two groups (n=116 [38%] for shunt device vs n=97 [31%] for sham procedure; p=0·11). Placement of an atrial shunt device did not reduce the total rate of heart failure events or improve health status in the overall population of patients with heart failure and ejection fraction of greater than or equal to 40%. Corvia Medical.

Shah SJ ，Borlaug BA ，Chung ES ，Cutlip DE ，Debonnaire P ，Fail PS ，Gao Q ，Hasenfuß G ，Kahwash R ，Kaye DM ，Litwin SE ，Lurz P ，Massaro JM ，Mohan RC ，Ricciardi MJ ，Solomon SD ，Sverdlov AL ，Swarup V ，van Veldhuisen DJ ，Winkler S ，Leon MB ，REDUCE LAP-HF II investigators ... -  《-》

Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure.

Borlaug BA ，Blair J ，Bergmann MW ，Bugger H ，Burkhoff D ，Bruch L ，Celermajer DS ，Claggett B ，Cleland JGF ，Cutlip DE ，Dauber I ，Eicher JC ，Gao Q ，Gorter TM ，Gustafsson F ，Hayward C ，van der Heyden J ，Hasenfuß G ，Hummel SL ，Kaye DM ，Komtebedde J ，Massaro JM ，Mazurek JA ，McKenzie S ，Mehta SR ，Petrie MC ，Post MC ，Nair A ，Rieth A ，Silvestry FE ，Solomon SD ，Trochu JN ，Van Veldhuisen DJ ，Westenfeld R ，Leon MB ，Shah SJ ，REDUCE LAP-HF-II Investigators ... -  《-》

One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: A Ran

Shah SJ ，Feldman T ，Ricciardi MJ ，Kahwash R ，Lilly S ，Litwin S ，Nielsen CD ，van der Harst P ，Hoendermis E ，Penicka M ，Bartunek J ，Fail PS ，Kaye DM ，Walton A ，Petrie MC ，Walker N ，Basuray A ，Yakubov S ，Hummel SL ，Chetcuti S ，Forde-McLean R ，Herrmann HC ，Burkhoff D ，Massaro JM ，Cleland JGF ，Mauri L ... -  《-》